Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Table 5 ASAS40 and BASDAI 50 response rates at week 12 in patients with AS stratified by prior anti-TNF therapy

	ASAS40			BASDAI 50
	Response rate, n/N(%)	Unadjusted odds ratio	Pvalue	Response rate, n/N(%)	Unadjusted odds ratio	Pvalue
		(95% CI)			(95% CI)
History of prior anti-TNF therapy
Prior ETN or IFX or both	115/305 (37.7)	0.41 (0.32 to 0.54)	< 0.001	128/314 (40.8)	0.40 (0.31 to 0.53)	< 0.001
No prior ETN/IFX^a	518/873 (59.3)			561/890 (63.0)
Prior TNF antagonist(s)
ETN only	25/81 (30.9)	0.93 (0.47 to 1.83)	0.083	27/81 (33.3)	0.98 (0.51 to 1.90)	0.033
IFX only	66/150 (44.0)	1.64 (0.91 to 2.93)		75/156 (48.1)	1.82 (1.03 to 3.20)
ETN and IFX^a	24/74 (32.4)			26/77 (33.8)
Reason for discontinuation of prior TNF antagonist
Loss of response	46/108 (42.6)	2.09 (1.05 to 4.14)	0.108	47/112 (42.0)	2.03 (1.03 to 4.03)	0.059
Intolerance	20/52 (38.5)	1.76 (0.79 to 3.91)		25/54 (46.3)	2.42 (1.11 to 5.30)
Lack of response^a	16/61 (26.2)			16/61 (26.2)

^aUsed as reference value. AS, ankylosing spondylitis; ASAS40, Assessment of SpondyloArthritis international Society 40% response; BASDAI 50, Bath AS Disease Activity Index 50% response; CI, confidence interval; ETA, etanercept; IFX, infliximab; TNF, tumor necrosis factor.

ISSN: 1478-6362